Bioblast Pharma (ORPN) News Today → Gold Mania (From Stansberry Research) (Ad) Buy ORPN with Qtrade Free ORPN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineUmbrella Labs Elevates Biotechnological Frontiers with Launch of ALPHA MSH PEPTIDE 10MG VIALmsn.com - April 23 at 7:31 PMEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastomamarkets.businessinsider.com - April 10 at 7:48 PMAnaptysBio Inc.barrons.com - March 14 at 7:15 AMWhat's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?msn.com - February 23 at 12:39 PMLantern Pharma Inc Ordinary Shares LTRNmorningstar.com - February 23 at 7:39 AMQBiotics wins FDA orphan status for rainforest-derived cancer drugmsn.com - February 18 at 7:13 PMPBSV Pharma-Bio Serv, Inc.seekingalpha.com - February 18 at 2:12 PMAnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosismarkets.businessinsider.com - February 5 at 8:13 PMLumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officermarkets.businessinsider.com - January 4 at 5:18 PMPlus Therapeutics Shares Jump Premarket on FDA Orphan Designationmarketwatch.com - November 3 at 8:58 AMChangzhou Qianhong Bio-Pharma Co. Ltd. Awsj.com - March 31 at 11:06 PM2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for Developmentmarketwatch.com - March 1 at 11:05 PMSpinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028marketwatch.com - February 18 at 1:51 PMSpinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028marketwatch.com - February 15 at 7:25 PMBioBlast Scant Data Links Drug to Improved Swallowing in Patientsthestreet.com - February 13 at 7:34 PMBioMarin: Opportunity To Score Home Run With Latest Regulatory Advancementsseekingalpha.com - January 30 at 7:43 PMSpinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028marketwatch.com - January 18 at 1:10 PMOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027finance.yahoo.com - October 16 at 11:59 AMENLV Enlivex Therapeutics Ltd.seekingalpha.com - September 21 at 6:19 PMBioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans Progressivamarketwatch.com - August 31 at 9:23 PMBioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidatemsn.com - August 31 at 4:22 PMAro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Diseasefinance.yahoo.com - August 12 at 8:30 AMBioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 11 at 5:15 PMBiosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic Syndromesfinance.yahoo.com - August 1 at 9:41 AMCitius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphomamarkets.businessinsider.com - July 12 at 8:41 AMGlobal Orphan Drugs Global Market Report (2022 to 2031) - Featuring Amgen, Biogen, Novartis and Novo Nordisk Among Others - ResearchAndMarkets.comapnews.com - July 8 at 9:12 AMPyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDAapnews.com - July 7 at 8:29 AMAura Biosciences Gets Fast Track Designation for AU-011 Bladder Cancer Treatmentmarketwatch.com - June 30 at 7:37 AMProlacta Bioscience Appoints David Steinberg as Chief Financial Officermarkets.businessinsider.com - June 7 at 9:45 AMENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancerapnews.com - May 25 at 2:17 AMStealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophyfinance.yahoo.com - May 12 at 8:07 AMGlobal Genetic Disorders Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021prnewswire.com - September 17 at 7:36 PM Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address The Next Nvidia? (Ad)The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about. Go here now for this breaking story. ORPN Media Mentions By Week ORPN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORPN News Sentiment▼0.000.42▲Average Medical News Sentiment ORPN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORPN Articles This Week▼00▲ORPN Articles Average Week Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bellerophon Therapeutics News Today Evofem Biosciences News Today Aditxt News Today Sunshine Biopharma News Today China SXT Pharmaceuticals News Today Evelo Biosciences News Today SciSparc News Today Athersys News Today Aptevo Therapeutics News Today Ampio Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORPN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe only AI company you should be looking atBehind the MarketsMysterious Gold Leverage Just AnnouncedStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.